LLY

890.37

+1.41%↑

JNJ

242.43

+0.9%↑

ABBV

212.4

+1.3%↑

NVS

150.25

+1.35%↑

MRK

117.53

-1.8%↓

LLY

890.37

+1.41%↑

JNJ

242.43

+0.9%↑

ABBV

212.4

+1.3%↑

NVS

150.25

+1.35%↑

MRK

117.53

-1.8%↓

LLY

890.37

+1.41%↑

JNJ

242.43

+0.9%↑

ABBV

212.4

+1.3%↑

NVS

150.25

+1.35%↑

MRK

117.53

-1.8%↓

LLY

890.37

+1.41%↑

JNJ

242.43

+0.9%↑

ABBV

212.4

+1.3%↑

NVS

150.25

+1.35%↑

MRK

117.53

-1.8%↓

LLY

890.37

+1.41%↑

JNJ

242.43

+0.9%↑

ABBV

212.4

+1.3%↑

NVS

150.25

+1.35%↑

MRK

117.53

-1.8%↓

Kodu・Aktsiate loetelu・Mirati Therapeutics Inc

Mirati Therapeutics Inc

Avatud

SektorTervishoid

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	-0.05% downside

Uudiste sentiment

By Acuity

25%

75%

56 / 349 Pingereas Healthcare

Mirati Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

27. märts 2026, 17:33 UTC

Uudisväärsed sündmused

ECB Should Not Rush Its Response to Iran Conflict, Says Schnabel -- Update

27. märts 2026, 17:00 UTC

Uudisväärsed sündmused

ECB Shouldn't Rush Its Response to Iran Conflict, Schnabel Says

27. märts 2026, 16:03 UTC

Uudisväärsed sündmused

Fertilizer Maker Yara Warns Farmers Are Being Squeezed by Price Surge Amid War -- Commodities Roundup

29. märts 2026, 23:47 UTC

Market Talk

Uudisväärsed sündmused

Gold Falls Amid Rising Inflation Fears -- Market Talk

29. märts 2026, 23:46 UTC

Market Talk

Uudisväärsed sündmused

Nikkei May Fall on Fears About Shortage of Petrochemical Products -- Market Talk

29. märts 2026, 23:35 UTC

Market Talk

Uudisväärsed sündmused

Oil Rises on Supply-Disruption Concerns Spurred by Widening Mideast Conflict -- Market Talk

29. märts 2026, 23:23 UTC

Market Talk

Australia's National Cabinet to Avoid Covid-Style Measures -- Market Talk

29. märts 2026, 22:34 UTC

Market Talk

Macroeconomic Tailwind for Warehouse Dissipates -- Market Talk

29. märts 2026, 22:09 UTC

Market Talk

Amplitude's Next Well "Effectively a Must-Win" for Growth Thesis -- Market Talk

29. märts 2026, 21:06 UTC

Market Talk

Uudisväärsed sündmused

Australia's Economy Could Already Be Contracting Amid Oil Shock -- Market Talk

29. märts 2026, 21:03 UTC

Market Talk

Australia's Government Wants to Avoid Heavy Handed Oil Shock Response -- Market Talk

29. märts 2026, 21:01 UTC

Market Talk

Uudisväärsed sündmused

Australian National Cabinet Meeting to Focus on Oil Supply -- Market Talk

29. märts 2026, 09:30 UTC

Omandamised, ülevõtmised, äriostud

Food Mega-Mergers Hardly Ever Work. Could McCormick-Unilever Be Different? -- Heard on the Street -- WSJ

28. märts 2026, 08:20 UTC

Market Talk

Health Care Roundup: Market Talk

27. märts 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

27. märts 2026, 19:16 UTC

Market Talk

Uudisväärsed sündmused

Oil Futures Rise On Uncertainty Ahead of Weekend -- Market Talk

27. märts 2026, 19:07 UTC

Market Talk

U.S. Natural Gas Gains As April Contract Expires -- Market Talk

27. märts 2026, 19:04 UTC

Market Talk

Gold Rises But Can't Finish the Week Positive -- Market Talk

27. märts 2026, 19:03 UTC

Market Talk

Uudisväärsed sündmused

Global Forex and Fixed Income Roundup: Market Talk

27. märts 2026, 19:02 UTC

Market Talk

Uudisväärsed sündmused

Among Central Banks, Canada Has Room to Handle Oil Inflation -- Market Talk

27. märts 2026, 18:12 UTC

Market Talk

Foreign Fuels and Feedstocks to Get RINs Until 2028 -- Market Talk

27. märts 2026, 17:36 UTC

Uudisväärsed sündmused

The Iran War and Oil Prices Bring Risk of Deeper Market Lows. There Are Echoes of 2008. -- Barrons.com

27. märts 2026, 17:34 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Delivery Hero Shares Bounce as Stake-Sale Report Whets Investor Appetites -- Market Talk

27. märts 2026, 17:29 UTC

Market Talk

U.S. Oil Rig Count Falls By 5 to 409 -- Market Talk

27. märts 2026, 16:38 UTC

Market Talk

Carnival's Outlook Assumes Oil Prices Will Come Down -- Market Talk

27. märts 2026, 16:32 UTC

Market Talk

Uudisväärsed sündmused

Chinese Exposure to Higher Energy Costs Seen as Limited -- Market Talk

27. märts 2026, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

27. märts 2026, 15:43 UTC

Market Talk

Uudisväärsed sündmused

Hormuz Closure Sends Tanker Rates to Record Highs -- Market Talk

27. märts 2026, 15:25 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27. märts 2026, 15:25 UTC

Market Talk

Swiss Franc Dented by Rising European Yields, SNB Intervention Threats -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Mirati Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

-0.05% langus

12 kuu keskmine prognoos

Keskmine 58.67 USD -0.05%

Kõrge 59 USD

Madal 58 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Mirati Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi Mirati Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

56 / 349 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

EBITDA

Ärikasum

Ettevõttest Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.